Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 88 publications.

Smith A, Gore J, Chisolm S, Squires P, Li H, Dave HK, Vass C, Liu X, Mansfield C. Non-muscle invasive bladder cancer treatment selection in an emerging treatment era: a patient preference study. Poster presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium; February 13, 2025. San Francisco, CA. [abstract] J Clin Oncol. 2025 Feb 18; 43(Suppl 5):754. doi: 10.1200/JCO.2025.43.5_suppl.754

Smith A, Gore J, Chisolm S, Squires P, Li H, Franco S, Vass C, Liu X, Mansfield C. Muscle invasive bladder cancer treatment selection in an emerging treatment era: a patient preference study. Poster presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium; February 13, 2025. San Francisco, CA. [abstract] J Clin Oncol. 2025; 43(Suppl 5):753.

Shore S, Ervin C, Kosa K, Fehnel S, Salberg L, Butzner M, Heitner SB, Jacoby D, Saberi S. Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathy. BMJ Open. 2024 Sep 17;14(9):e081323. doi: 10.1136/bmjopen-2023-081323

Loria-Rebolledo LE, Abbott M, Antunes M, Norwood P, Ryan M, Watson V, Wu H. Public preferences and willingness to pay for a net zero NHS: a protocol for a discrete choice experiment in England and Scotland. BMJ Open. 2024 Jun 21;14(6):082863. doi: 10.1136/bmjopen-2023-082863

Razavi P, Ahmed M, Roush A, Parikh R, Hitchens A, Shen S, Safonov A, Jhaveri K, Robson M, Peacock N, Ma Y, Santarsiero E, Ganapathy V, Shah R, Amaefule A, Lteif A, Blakely J. Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US. J Clin Oncol. 2024 May;42(Suppl 16):e12533.

Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-99. doi: 10.1200/JCO.23.00170

Hansford HJ, Cashin AG, Jones MD, Swanson SA, Islam N, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sterne J, Sharp MK, Stuart EA, Hernan MA, Lee H, McAuley JH. Development of the TrAnsparent ReportinG of observational studies Emulating a Target trial (TARGET) guideline. BMJ Open. 2023 Sep 12;13(9):e074626. doi: 10.1136/bmjopen-2023-074626

Vazquez ML, Vilaplana-Carnerero C, Gomez-Lumbreras A, Prat-Vallverdu O, Marsal JR, Urgell CV, Giner-Soriano M, Morros R. Drug exposure during pregnancy in primary care: an algorithm and observational study from SIDIAP database, Catalunya, Spain. BMJ Open. 2023 Aug 22;13(8):e071335. doi: 10.1136/bmjopen-2022-071335

Edwards T, Norcross L, Fine J, Martin S, Coulouvrat C, Spears P, Herold CI, Ferrari G, Onwudiwe N. Side effects and impacts of extended adjuvant endocrine therapy: a qualitative study among women with HR+/HER2- breast cancer. Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023 Jun; 41(Suppl 16):e12509. doi: 10.1200/JCO.2023.41.16_suppl.e12509

Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Heterogeneity in physician and patient preferences for the treatment of renal cell carcinoma: evidence from latent class analysis. Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Franciso, CA. [abstract] J Clin Oncol. 2023 Feb 20; 41(Suppl 6):661. doi: 10.1200/JCO.2023.41.6_suppl.661

Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, Pinto CA, Poulos C. Patient and physician preferences for adjuvant treatment of renal cell carcinoma: a discrete-choice experiment. Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Franciso, CA. [abstract] J Clin Oncol. 2023 Feb 20; 41(Suppl 6):635. doi: 10.1200/JCO.2023.41.6_suppl.635

Grivas P, Barata PC, Moon H, Hutson TE, Gupta S, Sternberg CN, Dave V, Downey C, Shillington AC, Devgan G, Kirker M, Thakkar S, Katzenstein HM, Bhanegaonkar A, Liu F, Brown J, Sonpavde GP. Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II). Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Francisco, CA. [abstract] J Clin Oncol. 2023 Feb 1; 41(Suppl 4). doi: 10.1200/JCO.2023.41.6_suppl.465

Furqan M, Karanth S, Goyal RK, Shih Y, Cai B, Rombi J, Davis KL, Caro N, Saliba TR. Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14). Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023; 4((Suppl 16):e21112.

Shields GE, Wells A, Wright S, Vass C, Davies LM, Doherty P, Capobianco L. A discrete choice experiment to investigate preferences for psychological intervention in cardiac rehabilitation. BMJ Open. 2022 Nov 7;12(11):e062503. doi: 10.1136/bmjopen-2022-062503

Paik PK, Goyal RK, Cai B, Price M, Davis K, Derrien Ansquer V, Caro N, Saliba TR. Real-world assessment of clinical outcomes in NSCLC patients with MET exon 14 skipping mutation and brain metastases (BM) treated with capmatinib. Poster presented at the ASCO 2022 Annual Meeting; June 2022. Chicago, IL. [abstract] J Clin Oncol. 2022 Jun 2; 40(16_suppl):e21171. doi: 10.1200/JCO.2022.40.16_suppl.e21171

Hamadani M, Graham C, Liao L, Zhang K, Strat HM, Ungar D, Ai W, Chen L, Carlo-Stella C. Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2022 Jun;40(16_suppl):e19551.

Guilbert E, Perry R, Whitmarsh A, Sauchelli S. Short-term effectiveness of nutrition therapy to treat type 2 diabetes in low-income and middle-income countries: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2022 Mar 10;12(3):e056108. doi: 10.1136/bmjopen-2021-056108

Loria-Rebolledo LE, Ryan M, Watson V, Genie MG, Sakowsky RA, Powell D, Paranjothy S. Public acceptability of non-pharmaceutical interventions to control a pandemic in the UK: a discrete choice experiment. BMJ Open. 2022 Mar 8;12(3):e054155. doi: 10.1136/bmjopen-2021-054155

Nieuwenhuijsen MJ, Barrera-Gomez J, Basagana X, Cirach M, Daher C, Foraster Pulido M, Lungman T, Gasparrini A, Hoek G, de Hoogh K, Khomenko S, Khreis H, de Nazelle A, Ramos A, Rojas-Rueda D, Barboza EP, Tainio M, Thondoo M, Tonne C, Woodcock J, Mueller N. Study protocol of the European urban burden of disease project: a health impact assessment study. BMJ Open. 2022 Jan 20;12(1):e054270. doi: 10.1136/bmjopen-2021-054270

Mazza C, Alcock L, Aminian K, Becker C, Bertuletti S, Bonci T, Brown P, Brozgol M, Buckley E, Carsin AE, Caruso M, Caulfield B, Cereatti A, Chiari L, Chynkiamis N, Ciravegna F, Del Din S, Eskofier B, Evers J, Aymerich JG, Gazit E, Hansen C, Hausdorff JM, Helbostad JL, Hiden H, Hume E, Paraschiv-Ionescu A, Ireson N, Keogh A, Kirk C, Kluge F, Koch S, Kuderle A, Lanfranchi V, Maetzler W, Mico-Amigo ME, Mueller A, Neatrour I, Niessen M, Palmerini L, Pluimgraaff L, Reggi L, Salis F, Schwickert L, Scott K, Sharrack B, Sillen H, Singleton D, Soltani A, Taraldsen K, Ullrich M, Van Gelder L, Vereijken B, Vogiatzis I, Warmerdam E, Yarnall A, Rochester L. Technical validation of real-world monitoring of gait: a multicentric observational study. BMJ Open. 2021 Dec 2;11(12):e050785. doi: 10.1136/bmjopen-2021-050785

Connor MJ, Genie MG, Gonzalez M, Sarwar N, Thippu Jayaprakash K, Horan G, Hosking-Jervis F, Klimowska-Nassar N, Sukumar J, Pokrovska T, Basak D, Robinson A, Beresford M, Rai B, Mangar S, Khoo V, Dudderidge T, Falconer A, Winkler M, Watson V, Ahmed HU. Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study. BMJ Open. 2021 Nov 18;11(11):e048996. doi: 10.1136/bmjopen-2021-048996

Lee GO, Eisenberg JNS, Uruchima J, Vasco G, Smith SM, Van Engen A, Victor C, Reynolds E, MacKay R, Jesser KJ, Castro N, Calvopina M, Konstantinidis KT, Cevallos W, Trueba G, Levy K. Gut microbiome, enteric infections and child growth across a rural-urban gradient: protocol for the ECoMiD prospective cohort study. BMJ Open. 2021 Oct 22;11(10):e046241. doi: 10.1136/bmjopen-2020-046241

Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, Andre F. Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2–negative advanced breast cancer from SOLAR-1. J Clin Oncol. 2021 Jun 20;39(18):2005-15. doi: 10.1200/JCO.20.01139

Gold AL, Meza E, Ackley SF, Mungas DM, Whitmer RA, Mayeda ER, Miles S, Eng CW, Gilsanz P, Glymour MM. Are adverse childhood experiences associated with late-life cognitive performance across racial/ethnic groups: results from the Kaiser healthy aging and diverse life experiences study baseline. BMJ Open. 2021 Feb 5;11(2):e042125. doi: 10.1136/bmjopen-2020-042125

Motzer RJ, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Wang J, Pan J, Ayele Asfaw A, He CS, Mody K, Cella D. Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). Presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4502.

Wyrwicz L, Elimova E, Blum SI, Xiao H, Davenport E, Wang J, Hunter S, Li M, Kondo K, Mohler M. Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4066. doi: 10.1200/JCO.2021.39.15_suppl.4066

Cella D, Hackshaw MD, Vondeling GT, Bennett L, Garbinsky D, Saito K, Sugihara M, Bang YJ, Yamaguchi K, Shitara K. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4057. doi: 10.1200/JCO.2021.39.15_suppl.4057

Genie MG, Loria-Rebolledo LE, Paranjothy S, Powell D, Ryan M, Sakowsky RA, Watson V. Understanding public preferences and trade-offs for government responses during a pandemic: a protocol for a discrete choice experiment in the UK. BMJ Open. 2020 Nov 20;10(11):e043477. doi: 10.1136/bmjopen-2020-043477

Stirnadel-Farrant H, Mahajan A, Dhillon N, Patel N, Pokras S. Current treatment efficacy for metastatic soft tissue sarcoma: a targeted literature review. Poster presented at the 2020 ASCO Annual Meeting I; May 25, 2020. Chicago, IL. [abstract] J Clin Oncol. 2020 Jun; 38(15_Suppl). doi: 10.1200/JCO.2020.38.15_suppl.e23577

Richardson D, Zhan L, Reynolds M, Odom D, Hollis K, Mitra D, McRoy L, Jones C, Mahtani R, Hargis J. The effect of neutropenia on patient-reported functioning and Quality of Life (QOL) among palbociclib participants of the MADELINE Study. Poster presented at the 2020 ASCO Virtual Scientific Program; June 2020. [abstract] J Clin Oncol. 2020 Jun; 38(2020):1064. doi: 10.1200/JCO.2020.38.15_suppl.1064

Falguera M, Vilanova MB, Alcubierre N, Granado-Casas M, Marsal JR, Miro N, Cebrian C, Mollo A, Franch-Nadal J, Mata-Cases M, Castelblanco E, Mauricio D. Prevalence of pre-diabetes and undiagnosed diabetes in the Mollerussa prospective observational cohort study in a semi-rural area of Catalonia. BMJ Open. 2020 Jan 20;10(1):033332. doi: 10.1136/bmjopen-2019-033332

Poonnen P, Dong O, Winski D, Reed SD, Vashistha V, Bates JS, Kelley MJ, Voora D. Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma. Poster presented at the 2020 Virtual American Society of Clinical Oncology Scientific Program Meeting; May 29, 2020. [abstract] J Clin Oncol. 2020; 38(15 Suppl):7075.

Dzimitrowicz H, Esterberg L, Miles L, Zanotti G, Borham A, Harrison MR. Provider referral patterns following nephrectomy in high-risk locoregional renal cell carcinoma. Poster presented at the 2020 Genitourinary Cancers ASCO Symposium; February 15, 2020. San Francisco, CA. [abstract] J Clin Oncol. 2020; 38(Suppl 6):abstr 636.

Messina AJ, Andrianov V, Mazzolenis D, Vidal-Fisher L. Emerging trends and utilization of patient-reported outcomes (PROs) in clinical trials of chimeric antigen receptor (CAR) T-cell therapies. J Clin Oncol. 2020;38(2020):e19142. doi: 10.1200/JCO.2020.38.15_suppl.e19142

Ribera A, Ferreira-Gonzalez I, Marsal JR, Oristrell G, Faixedas MT, Rosas A, Tizon-Marcos H, Rojas S, Labata C, Cardenas M, Homs S, Tomas-Querol C, Garcia-Picart J, Gomez-Hospital JA, Pijoan JI, Masotti M, Mauri J, Garcia Dorado D, VESA Study and Codi IAM Investigators. Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain). BMJ Open. 2019 Jul 23;9(7):e028114. doi: 10.1136/bmjopen-2018-028114

Fizazi K, Shore ND, Tammela T, Kuss I, Le Berre M, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC). Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(15_Suppl).

Kummar S, Mascarenhas L, Geoerger B, Turpin B, Cox, MC, Yu S, Nanda S, Hiemeyer F, Keating KN, Chirila C, Gnanasakthy A, Davenport E, Hong DS, Drilon AE. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. Poster presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(2019):6602.

Price M, Ravelo A, Sae-Hau M, Torney PA, Gonzalez V, Weiss ES, Mansfield C, Mange B, Comenencia Ortiz E, Masaquel A, Lamont Dawson K. Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: results from a national patient advocacy survey. Poster presented at the 2019 ASCO Annual Meeting; May 2019. [abstract] J Clin Oncol. 2019 May 26; 37(15_suppl):e18198. doi: 10.1200/JCO.2019.37.15_suppl.e18198

Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, Altman DG, Moons KGM, Hooft L. Uniformity in measuring adherence to reporting guidelines: the example of TRIPOD for assessing completeness of reporting of prediction model studies. BMJ Open. 2019 Apr 24;9(4):e025611. doi: 10.1136/bmjopen-2018-025611

Damen JAAG, Debray TPA, Pajouheshnia R, Reitsma JB, Scholten RJPM, Moons KGM, Hooft L. Empirical evidence of the impact of study characteristics on the performance of prediction models: a meta-epidemiological study. BMJ Open. 2019 Apr 1;9(4):e026160. doi: 10.1136/bmjopen-2018-026160

Wildenschild C, Riis AH, Ehrenstein V, Hatch EE, Wise LA, Rothman KJ, Sorensen HT, Mikkelsen EM. Fecundability among Danish women with a history of miscarriage: a prospective cohort study. BMJ Open. 2019 Jan;9(1):e023996. doi: 10.1136/bmjopen-2018-023996

Kawai AT, Martinez D, Saltus CW, Vassilev Z, Soriano-Gabarro M, Kaye JA. Incidence of skeletal-related events in men with castration-resistant prostate cancer. Poster presented at the Palliative and Supportive Care in Oncology Symposium; November 17, 2018. San Diego, CA. [abstract] J Clin Oncol. 2018 Nov 28; 36(34_suppl):188. doi: 10.1200/JCO.2018.36.34_suppl.188

Simou E, Britton J, Leonardi-Bee J. Alcohol and the risk of pneumonia: a systematic review and meta-analysis. BMJ Open. 2018 Aug 22;8(8):e022344. doi: 10.1136/bmjopen-2018-022344

Yuguero O, Melnick ER, Marsal JR, Esquerda M, Soler-Gonzalez J. Cross-sectional study of the association between healthcare professional's empathy and burnout and the number of annual primary care visits per patient under their care in Spain. BMJ Open. 2018 Jul 30;8(7):e020949. doi: 10.1136/bmjopen-2017-020949

Saif WM, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Beveridge T, Mirakhur B, Lubeck CA, Nagar SP, Soares H. The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018 Jun 1; 36(15_suppl):e16174. doi: 10.1200/JCO.2018.36.15_suppl.e16174

Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen MH, Bittoni M, Heyes A, Carbone DP. Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: a systematic review. J Clin Oncol. 2018 May 16;36(15_suppl):e21120-e. doi: 10.1200/JCO.2018.36.15_suppl.e21120

Pollard DJ, Brennan A, Dixon S, Waugh N, Elliott J, Heller S, Lee E, Campbell M, Basarir H, White D, REPOSE group. Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial. BMJ Open. 2018 Apr 7;8(4):e016766. doi: 10.1136/bmjopen-2017-016766

Druce KL, Cordingley L, Short V, Moore S, Hellman B, James B, Lunt M, Kyle SD, Dixon WG, McBeth J. Quality of life, sleep and rheumatoid arthritis (QUASAR): A protocol for a prospective UK mHealth study to investigate the relationship between sleep and quality of life in adults with rheumatoid arthritis. BMJ Open. 2018 Jan 26;8(1):e018752. doi: 10.1136/bmjopen-2017-018752

Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez Salas N, Martin M, Alonso V, Vera R, Gallego J, Capdevila J, Salud A, Nogue M, Maurel J, Guasch I, Montagut Viladot C, Lopez-Lopez C, Canas MA, Declara IM, Garcia-Albeniz X. Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial. Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; 36(2018):e3518.

Maiese E, Graham CN, Hawe E, Le Moine JG. Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma. Poster presented at the 2018 ASCO Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; p.e20037. doi: 10.1200/JCO.2018.36.15_suppl.e20037